PubRank

Webster K Cavenee

Author PubWeight™ 192.74‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007 49.11
2 Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007 17.20
3 Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005 15.42
4 The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002 8.62
5 A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A 2003 7.30
6 Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 2002 4.76
7 Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell 2008 4.71
8 Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc Natl Acad Sci U S A 2004 4.25
9 Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A 2007 3.63
10 Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012 3.44
11 Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006 3.31
12 Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov 2011 2.77
13 Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011 2.66
14 Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 2013 2.24
15 Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs. Genome Res 2007 2.16
16 Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 2004 2.06
17 Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 2013 2.00
18 Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 2003 1.99
19 mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab 2013 1.86
20 Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res 2009 1.79
21 EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 2009 1.79
22 Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A 2003 1.79
23 Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex. Mol Cell Biol 2004 1.67
24 Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005 1.66
25 Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci U S A 2003 1.66
26 Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 2002 1.61
27 A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 2003 1.56
28 The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 2007 1.53
29 PCAF modulates PTEN activity. J Biol Chem 2006 1.52
30 Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci U S A 2005 1.47
31 Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer 2011 1.45
32 A drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet 2009 1.43
33 MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res 2011 1.33
34 The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell 2006 1.30
35 Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS One 2010 1.27
36 Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 2002 1.27
37 Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest 2007 1.26
38 Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 2008 1.25
39 EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab 2013 1.23
40 Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A 2010 1.21
41 Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. J Clin Invest 2011 1.20
42 Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005 1.16
43 Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A 2012 1.15
44 KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. J Natl Cancer Inst 2010 1.14
45 Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Mol Biosyst 2010 1.11
46 Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proc Natl Acad Sci U S A 2012 1.08
47 De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 2013 1.07
48 Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle 2007 1.07
49 Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A 2009 1.07
50 Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc Natl Acad Sci U S A 2011 1.01
51 PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. Proc Natl Acad Sci U S A 2007 1.01
52 PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc Natl Acad Sci U S A 2013 1.00
53 Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest 2010 1.00
54 Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR. J Proteome Res 2011 0.98
55 Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Res 2014 0.98
56 EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest 2014 0.97
57 Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 2006 0.96
58 A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis 2013 0.94
59 A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma. PLoS Genet 2013 0.92
60 The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res 2013 0.91
61 Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. J Cell Sci 2011 0.91
62 PTEN: a novel anti-oncogenic function independent of phosphatase activity. Cell Cycle 2005 0.89
63 Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. Int J Cancer 2012 0.88
64 Restriction landmark genome scanning. Methods Mol Biol 2002 0.85
65 Stem cells for treating glioblastoma: how close to reality? Neuro Oncol 2009 0.85
66 Escape from targeted inhibition: the dark side of kinase inhibitor therapy. Cell Cycle 2010 0.83
67 Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle 2013 0.82
68 Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg 2007 0.82
69 A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression. J Neurochem 2002 0.82
70 Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube. Transgenic Res 2006 0.82
71 Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. Cell Cycle 2008 0.81
72 Muscling in on rhabdomyosarcoma. Nat Med 2002 0.80
73 CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain Pathol 2002 0.79